Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

9.43+0.2100+2.28%Vol 7671Y Perf 58.32%
Apr 9th, 2021 13:42 DELAYED
BID8.65 ASK9.47
Open9.22 Previous Close8.38
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     56.86
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★★★     78.24
Market Cap- 
Earnings Rating
Price Range Ratio 52W %
98.72 
Earnings Date
-

Today's Price Range

9.229.45

52W Range

4.819.49

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
14.30%
1 Month
26.58%
3 Months
10.94%
6 Months
86.73%
1 Year
58.32%
3 Years
39.70%
5 Years
109.56%
10 Years
234.08%

TickerPriceChg.Chg.%
CYCCP9.430.21002.28
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume767
Shares Outstanding0
Trades Count17
Dollar Volume48
Avg. Volume658
Avg. Weekly Volume723
Avg. Monthly Volume521
Avg. Quarterly Volume574

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (NASDAQ: CYCCP) stock closed at 9.43 per share at the end of the most recent trading day (a 2.28% change compared to the prior day closing price) with a volume of 767.0000 shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock CEO is Spiro Rombotis.

The one-year performance of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock stock is 58.32%, while year-to-date (YTD) performance is 34.14%. CYCCP stock has a five-year performance of 109.56%. Its 52-week range is between 4.81 and 9.49, which gives CYCCP stock a 52-week price range ratio of 98.72%

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 13.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.46%, a ROC of -40.58% and a ROE of -54.02%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock has a dividend yield of 6.85% with a dividend per share of $0.60 and a payout ratio of -%.

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock has a Buy technical analysis rating based on Technical Indicators (ADX : 13.30, ATR14 : 0.48, CCI20 : -29.80, Chaikin Money Flow : 0.04, MACD : -0.25, Money Flow Index : 12.90, ROC : 1.36, RSI : 37.94, STOCH (14,3) : 15.38, STOCH RSI : 0.00, UO : 8.82, Williams %R : -84.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

CEO: Spiro Rombotis

Telephone: +1 908 517-7330

Address: 200 Connell Drive, Berkeley Heights 07922, NJ, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

42%58%

Bearish Bullish

50%50%

Bearish Bullish

54%46%

News

Stocktwits